Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
- PMID: 26861005
- DOI: 10.2174/0929867323666160210124930
Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
Abstract
In this review we discuss drug design strategies directed to the development of potential anti-influenza A(H1N1) inhibitors of M2 ion channel, neuraminidase (NA), hemagglutinin (HA) and RNA-dependent RNA-polymerase complex (RdRp) major targets, following temporal chronology of their findings. Besides searching for new chemotypes, eventually active against new targets of influenza A (H1N1), the design of optimized analogues of proven drugs is largely pursued, taking into account the emerging insight into the mechanisms of resistance to existing antivirals. Computational studies are also summarized, in order to highlight the structural requirements for further chemical optimizations.
Similar articles
-
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. ChemMedChem. 2012. PMID: 22807317 Review.
-
Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.Biochem Biophys Res Commun. 2009 Aug 28;386(3):432-6. doi: 10.1016/j.bbrc.2009.06.016. Epub 2009 Jun 10. Biochem Biophys Res Commun. 2009. PMID: 19523442
-
Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.BMC Bioinformatics. 2016 Dec 22;17(Suppl 19):512. doi: 10.1186/s12859-016-1374-1. BMC Bioinformatics. 2016. PMID: 28155702 Free PMC article.
-
Strategies of development of antiviral agents directed against influenza virus replication.Curr Pharm Des. 2007;13(34):3531-42. doi: 10.2174/138161207782794248. Curr Pharm Des. 2007. PMID: 18220789 Review.
-
Progress of small molecular inhibitors in the development of anti-influenza virus agents.Theranostics. 2017 Feb 8;7(4):826-845. doi: 10.7150/thno.17071. eCollection 2017. Theranostics. 2017. PMID: 28382157 Free PMC article. Review.
Cited by
-
The RdRp genotyping of SARS-CoV-2 isolated from patients with different clinical spectrum of COVID-19.BMC Infect Dis. 2024 Mar 4;24(1):281. doi: 10.1186/s12879-024-09146-x. BMC Infect Dis. 2024. PMID: 38439047 Free PMC article.
-
Methods of Synthesis and Antiviral Activity of New 4-Alkyl-3-Nitro-1,4-Dihydroazolo[5,1-c][1,2,4]Triazin-4-ols.Chem Heterocycl Compd (N Y). 2021;57(4):473-478. doi: 10.1007/s10593-021-02926-2. Epub 2021 May 12. Chem Heterocycl Compd (N Y). 2021. PMID: 33994554 Free PMC article.
-
Carambolaside W Inhibited H1N1 Influenza Virus-Induced Oxidative Stress through STAT-3/BCL-XL Signaling Pathway.Viruses. 2023 Aug 31;15(9):1858. doi: 10.3390/v15091858. Viruses. 2023. PMID: 37766266 Free PMC article.
-
Nisoldipine Inhibits Influenza A Virus Infection by Interfering with Virus Internalization Process.Viruses. 2022 Dec 8;14(12):2738. doi: 10.3390/v14122738. Viruses. 2022. PMID: 36560742 Free PMC article.
-
RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases.J Mol Struct. 2022 Feb 15;1250:131756. doi: 10.1016/j.molstruc.2021.131756. Epub 2021 Oct 17. J Mol Struct. 2022. PMID: 34690363 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials